The market demands for higher productivity and lower costs have led biopharmaceutical contract manufacturers (CMOs) to investigate and adopt new, sometimes disruptive, process technologies. CMOs continue to invest in upstream and downstream process technologies to meet these demands. Adoption of new...
Over the past decade, pharmaceutical and biotechnology
companies have increased their use of contractors for
biopharmaceutical production. This includes both the production
of drug substances as well as drug products. Over the next few years,
this trend will continue as drug developers project a...